- Home
- JD vs EW Comparison
JD vs EW Comparison
Compare JD & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JD
- EW
- Stock Information
- Founded
- JD 2006
- EW 1958
- Country
- JD China
- EW United States
- Employees
- JD N/A
- EW N/A
- Industry
- JD Other Specialty Stores
- EW Industrial Specialties
- Sector
- JD Consumer Discretionary
- EW Health Care
- Exchange
- JD Nasdaq
- EW Nasdaq
- Market Cap
- JD 47.4B
- EW 40.7B
- IPO Year
- JD 2014
- EW 2000
- Fundamental
- Price
- JD $33.86
- EW $73.68
- Analyst Decision
- JD Strong Buy
- EW Buy
- Analyst Count
- JD 10
- EW 20
- Target Price
- JD $49.10
- EW $79.45
- AVG Volume (30 Days)
- JD 13.9M
- EW 4.3M
- Earning Date
- JD 05-13-2025
- EW 04-23-2025
- Dividend Yield
- JD 2.89%
- EW N/A
- EPS Growth
- JD 76.40
- EW 201.77
- EPS
- JD 3.68
- EW 7.02
- Revenue
- JD $158,761,901,950.00
- EW $5,522,300,000.00
- Revenue This Year
- JD $9.85
- EW $10.07
- Revenue Next Year
- JD $5.83
- EW $9.65
- P/E Ratio
- JD $9.21
- EW $10.54
- Revenue Growth
- JD 6.84
- EW N/A
- 52 Week Low
- JD $24.13
- EW $58.93
- 52 Week High
- JD $47.82
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- JD 42.05
- EW 52.18
- Support Level
- JD $33.37
- EW $74.25
- Resistance Level
- JD $34.65
- EW $76.13
- Average True Range (ATR)
- JD 0.70
- EW 1.75
- MACD
- JD 0.33
- EW -0.02
- Stochastic Oscillator
- JD 68.21
- EW 56.51
About JD JD.com Inc.
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.